Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

NCT04511637 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Clinical Pharmacology

Interventions

DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form

Sponsor

Bayer

Collaborators

[object Object]